MSB 2.91% $1.06 mesoblast limited

Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-184

  1. 571 Posts.
    lightbulb Created with Sketch. 160
    How do you know that the urology surgeon is the same Rakesh Patel as the one that made the submission? To me it reads pretty amateurish, and uses poor English. Not the sort of thing someone with Dr in front of their name writes. I suspect this is a retail investor who thinks their opinion matters to the FDA.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.